Inhibition of DNA methylation reverses norepinephrine-induced cardiac hypertrophy in rats

Cardiovascular Research

Volumn 101, Issue 3, 2014, Pages 373-382

  Xiao, Daliao ^a,b   Dasgupta, Chiranjib ^b   Chen, Man ^b   Zhang, Kangling ^b   Buchholz, John ^b   Xu, Zhice ^a,b   Zhang, Lubo ^a,b  

^a THE FIRST AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

^b LOMA LINDA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Failure; Heart; Hypertrophy; Methylation; Proteomic

Indexed keywords

FAILURE; HEART; HYPERTROPHY; METHYLATION; PROTEOMIC;

ANIMALS; BLOOD PRESSURE; CARDIOMEGALY; DISEASE MODELS, ANIMAL; DNA METHYLATION; HEART FAILURE; MALE; NOREPINEPHRINE; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84894518920     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvt264     Document Type: Article

References (46)

1. Cohn JN, Levine TB, OlivariMT, Garberg V, Lura D, Francis GS et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure.NEngl J Med 1984;311:819-824.
2. Kaye DM, Lefkovits J, Jennings GL, Bergin P, Broughton A, Esler MD. Adverse consequences of high sympathetic nervous activity in the failing human heart. J Am Coll Cardiol 1995;26:1257-12563.
3. Floras JS. Sympathetic nervous system activation in human heart failure: clinical implications of an updated model. J Am Coll Cardiol 2009;54:375-385.
4. Francis GS, Cohn JN, Johnson G, Rector TS, Goldman S, Simon A. Plasma norepinephrine, plasma renin activity, and congestive heart failure. Relations to survival and the effects of therapy in V-HeFT II. The V-HeFT VA Cooperative Studies Group. Circulation 1993;87:V140-V148.
5. Movassagh M, Choy MK, GoddardM, Bennett MR, Down TA, Foo RS. DifferentialDNA methylation correlates with differential expression of angiogenic factors in human heart failure. PLoS ONE 2010;5:e8564.
6. Movassagh M, Choy MK, Knowles DA, Cordeddu L, Haider S, Down T et al. Distinct epigenomic features in end-stage failing human hearts. Circulation 2011;124:2411-2422.
7. Trivedi CM, Luo Y, Yin Z, Zhang M, ZhuW, Wang T et al. Hdac2 regulates the cardiac hypertrophic response by modulating Gsk3 beta activity. Nat Med 2007;13:324-331.
8. Zhang CL, McKinsey TA, Chang S, Antos CL, Hill JA, Olson EN. Class II histone deacetylases act as signal-responsive repressors of cardiac hypertrophy. Cell 2002; 110:479-488.
9. Lawrence J, Chen M, Xiong F, Xiao D, Zhang H, Buchholz JN et al. Foetal nicotine exposure causes PKCepsilon gene repression by promoter methylation in rat hearts. Cardiovasc Res 2011;89:89-97.
10. Patterson AJ, Chen M, Xue Q, Xiao D, Zhang L. Chronic prenatal hypoxia induces epigenetic programming of PKC1 gene repression in rat hearts. Circ Res 2011;107: 365-673.
11. Xiong F, Xiao D, Zhang L. Norepinephrine causes epigenetic repression of PKC1gene in rodent hearts by activating Nox1-dependent reactive oxygen species production. FASEB J 2012;26:2753-2763.
12. Quinlivan EP, Gregory JF III. DNA digestion to deoxyribonucleoside: a simplified one-step procedure. Anal Biochem 2008;373:383-385.
13. Zhang K, Haynes TA, Filippova M, Filippov V, Duerksen-Hughes PJ. Quantification of ceramide levels in mammalian cells by high performance liquid chromatography coupled to tandem mass spectrometry with multiple-reaction- monitoring mode (HPLC-MS/MS-MRM). Anal Methods 2011;3:1193-1197.
14. Xiong L, Darwanto A, Sharma S, Herring J, Hu S, Filippova M et al. Mass spectrometric studies on epigenetic interaction networks in cell differentiation. J Biol Chem 2011;286: 13657-13668.
15. Zhang K, Schrag M, Crofton A, Trivedi R, Vinters H, KirschW. Targeted proteomics for quantification of histone acetylation in Alzheimer's disease. Proteomics 2012;12: 1261-1268.
16. Unwin RD, Smith DL, Blinco D, Wilson CL, Miller CJ, Evans CA et al. Quantitative proteomics reveals posttranslational control as a regulatory factor in primary hematopoietic stem cells. Blood 2006;107:4687-4694.
17. van Ulsen P, Kuhn K, Prinz T, Legner H, Schmid P, Baumann C et al. Identification of proteins of Neisseria meningitidis induced under iron-limiting conditions using the isobaric tandem mass tag (TMT) labeling approach. Proteomics 2009;9:1771-1781.
18. Masuo K, Katsuya T, Sugimoto K, Kawaguchi H, Rakugi H, Ogihara T et al. High plasma norepinephrine levels associated with beta2-adrenoceptor polymorphisms predict future renal damage in nonobese normotensive individuals. Hypertens Res 2007;30: 503-511.
19. Alikhani-Koopaei R, Fouladkou F, Frey FJ, Frey BM. Epigenetic regulation of 11 betahydroxysteroid dehydrogenase type 2 expression. J Clin Invest 2004;114:1146-1157.
20. DornGWII, Force T. Protein kinase cascades in the regulation of cardiac hypertrophy. J Clin Invest 2005;115:527-537.
21. Wu G, Toyokawa T, Hahn H, Dorn GW II. Epsilon protein kinase C in pathological myocardial hypertrophy. Analysis by combined transgenic expression of translocation modifiers and Galphaq. J Biol Chem 2000;275:29927-29930.
22. Chen L, Hahn H, Wu G, Chen CH, Liron T, Schechtman D et al. Opposing cardioprotective actions and parallel hypertrophic effects of delta PKC and epsilon PKC. Proc Natl Acad Sci USA 2001;98:11114-11119.
23. Mochly-Rosen D, Wu G, Hahn H, Osinska H, Liron T, Lorenz JN et al. Cardiotrophic effects of protein kinase C epsilon: analysis by in vivo modulation of PKCepsilon translocation. Circ Res 2000;86:1173-1179.
24. Gray MO, Zhou HZ, Schafhalter-Zoppoth I, Zhu P, Mochly-Rosen D, Messing RO. Preservation of base-line hemodynamic function and loss of inducible cardioprotection in adult mice lacking protein kinase C epsilon. J Biol Chem 2004;279:3596-3604.
25. Ping P, Zhang J, PierceWMJr, Bolli R. Functional proteomic analysis of protein kinase C epsilon signaling complexes in the normal heart and during cardioprotection. Circ Res 2001;88:59-62.
26. Snoeckx LH, Cornelussen RN, Van Nieuwenhoven FA, Reneman RS, Van Der Vusse GJ. Heat shock proteins and cardiovascular pathophysiology. Physiol Rev 2001;81: 1461-1497.
27. Roche M, Rondeau P, Singh NR, Tarnus E, Bourdon E. The antioxidant properties of serum albumin. FEBS Lett 2008;582:1783-1787.
28. Trent JT III, Hargrove MS.Aubiquitously expressed human hexacoordinate hemoglobin. J Biol Chem 2002;277:19538-19545.
29. Dhalla NS, TemsahRM, Netticadan T. Role of oxidative stress in cardiovascular diseases. J Hypertens 2000;18:655-673.
30. Pimentel DR, Amin JK, Xiao L, Miller T, Viereck J, Oliver-Krasinski J et al. Reactive oxygen species mediate amplitude-dependent hypertrophic and apoptotic responses to mechanical stretch in cardiac myocytes. Circ Res 2001;89:453-460.
31. Herman DS, Lam L, Taylor MR, Wang L, Teekakirikul P, Christodoulou D et al. Truncations of titin causing dilated cardiomyopathy. N Engl J Med 2012;366:619-628.
32. McNally EM. Genetics: broken giant linked to heart failure. Nature 2012;483:281-282.
33. LeWinterMM, Wu Y, Labeit S, Granzier H. Cardiac titin: structure, functions and role in disease. Clin Chim Acta 2007;375:1-9.
34. Kordowska J, Huang R, Wang CL. Phosphorylation of caldesmon during smooth muscle contraction and cell migration or proliferation. J Biomed Sci 2006;13:159-172.
35. Yan W, Wang P, Zhao CX, Tang J, Xiao X, Wang DW. Decorin gene delivery inhibits cardiac fibrosis in spontaneously hypertensive rats by modulation of transforming growth factor-beta/Smad and p38 mitogen-activated protein kinase signaling pathways. Hum Gene Ther 2009;20:1190-1200.
36. Baba H, Ishiwata T, Takashi E, Xu G, Asano G. Expression and localization of lumican in the ischemic and reperfused rat heart. Jpn Circ J 2001;65:445-450.
37. Ahmed MS, Oie E, Vinge LE, Yndestad A, Andersen GG, Andersson Y et al. Induction of myocardial biglycan in heart failure in rats-an extracellular matrix component targeted by AT1 receptor antagonism. Cardiovasc Res 2003;60:557-568.
38. Wiberg C, HeinegardD, Wenglen C, Timpl R, Morgelin M. Biglycan organizes collagen VI into hexagonal-like networks resembling tissue structures. J Biol Chem 2002;277: 49120-49126.
39. Sarkar S, LeamanDW, Gupta S, Sil P, YoungD, MoreheadAet al. Cardiac overexpression of myotrophin triggers myocardial hypertrophy and heart failure in transgenic mice. J Biol Chem 2004;279:20422-20434.
40. Gupta S, Purcell NH, Lin A, Sen S. Activation of nuclear factor-kappaB is necessary for myotrophin-induced cardiac hypertrophy. J Cell Biol 2002;159:1019-1028.
41. Mukherjee DP, McTiernan CF, Sen S. Myotrophin induces early response genes and enhances cardiac gene expression. Hypertension 1993;21:142-148.
42. Sil P, Misono K, Sen S. Myotrophin in human cardiomyopathic heart. Circ Res 1993;73: 98-108.
43. Kong Y, Shelton JM, Rothermel B, Li X, Richardson JA, Bassel-Duby R et al. Cardiac-specific LIM protein FHL2 modifies the hypertrophic response to beta-adrenergic stimulation. Circulation 2001;103:2731-2738.
44. Granzier HL, Radke MH, Peng J, Westermann D, Nelson OL, Rost K et al. Truncation of titin's elastic PEVK region leads to cardiomyopathy with diastolic dysfunction. Circ Res 2009;105:557-564.
45. Radke MH, Peng J, Wu Y, MeNabb M, Nelson OL, GranzierH et al. Targeted deletion of titin N2B region leads to diastolic dysfunction and cardiac atrophy. Proc Natl Acad Sci USA 2007;104:3444-3449.
46. Guo JU, Su Y, Zhong C, Ming GL, Song H. Hydroxylation of 5-methylcytosine by TET1 promotes active DNA demethylation in the adult brain. Cell 2011;145: 423-434.